Fimasartan/hydrochlorothiazide

Drug Profile

Fimasartan/hydrochlorothiazide

Alternative Names: BKE-001; Diarakhor; Kanarb plus

Latest Information Update: 21 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Boryung Pharmaceutical
  • Developer Boryung Pharmaceutical; Stendhal Mexico
  • Class
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Essential hypertension

Most Recent Events

  • 07 Aug 2017 Boryung Pharmaceutical initiates enrolment in the phase III FITNESS trial for Essential hypertension in South Korea (PO) (NCT03246555)
  • 04 Aug 2017 Phase-III development is ongoing in South Korea (Boryung Pharmaceutical pipeline, August 2017)
  • 01 Feb 2014 Stendhal completes the phase III FIRME-1 trial in Essential hypertension in Mexico (NCT02466490)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top